The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Novel BCMA-targeting therapies to treat TCE relapsed/refractory multiple myeloma
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the need for new drugs with novel mechanisms to treat relapsed/refractory (R/R) multiple myeloma. He notes that frontline treatments often involve proteasome inhibitors, IMiDs, and CD38-targeting immunotherapies, leading to patients becoming triple-class exposed (TCE) and reducing the effectiveness of these agents in the R/R setting. Prof. Leleu emphasizes the potential of BCMA-targeting therapies, including bispecific antibodies, antibody-drug conjugates (ADCs), and CAR T-cells, to address this unmet need, offering the possibility of fixed-duration treatments. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
